Toxicologic Pathology Forum: Opinion on Considerations for Determination of Adverse Versus Nonadverse Nerve Fiber Degeneration in Nonclinical Toxicity Studies of Oligonucleotides Delivered Directly Into the Intrathecal Space
Published online on March 25, 2026
Abstract
Toxicologic Pathology, Ahead of Print.
Determination of adversity and the no observed adverse effect level (NOAEL) in nonclinical toxicity studies are important components in the overall assessment of the potential for human risk during pharmaceutical development. Resources exist to guide ...
Determination of adversity and the no observed adverse effect level (NOAEL) in nonclinical toxicity studies are important components in the overall assessment of the potential for human risk during pharmaceutical development. Resources exist to guide ...